Meltwind Advisory

Natrox is a wound-care company that has developed an innovative device designed to enhance the healing of chronic wounds. This battery-powered medical device generates a continuous flow of pure humidified oxygen from ambient air and delivers it directly to the wound site through a specialized Oxygen Delivery System. This process refreshes the wound while allowing the natural drainage of fluids. Natrox is particularly beneficial for patients with chronic wounds, including diabetic foot ulcers, pressure ulcers, and arterial and venous leg ulcers. Additionally, the company utilizes artificial intelligence to analyze wound images, enabling healthcare professionals to monitor healing progress and communicate in real-time about patient treatment.

Shift Bioscience is focused on using advanced simulation techniques to address the challenges of aging and age-related diseases. The company has developed a high-throughput aging biomarker that facilitates the identification of rejuvenation gene factors through AI-driven cell simulations. By employing deep learning technology, Shift tests extensive gene combinations to discover potential drugs that can reverse aging effects and repair mitochondrial genes. The ultimate goal is to create a single family of drugs capable of treating various diseases associated with aging, thereby promoting sustained health into old age through accessible prescriptions.

NanoSyrinx is a biotechnology company focused on developing an innovative system for the targeted delivery of therapeutic proteins and peptides directly into the cytosol of cells. By employing synthetic biology techniques, the company aims to create a groundbreaking method for drug delivery that enhances the efficacy, safety, and cost-effectiveness of treatments in the biopharmaceutical sector. This novel approach allows for precise delivery of therapeutic agents, potentially improving treatment outcomes for patients by ensuring that the drugs reach their intended cellular targets.

Infinitopes is a cancer research organization focused on enhancing the immune system to prevent metastases and ultimately save lives. The company develops healthcare systems and therapeutic designs that integrate advanced tumor target identification technologies with efficient vector delivery systems. By applying this innovative platform in early-stage clinical trials, Infinitopes aims to improve patient outcomes in the fight against cancer and tumors, offering new hope for those affected by these diseases.

Qureight is an imaging analytics company focused on enhancing the understanding of respiratory diseases, including Idiopathic Pulmonary Fibrosis and lung cancer. It develops a clinical data curation and analytics platform that integrates technology and life sciences to expedite drug development. By leveraging artificial intelligence, Qureight collaborates with hospitals, pharmaceutical companies, and software developers to analyze extensive clinical datasets. This approach aids in structuring medical images alongside clinical metadata, allowing healthcare professionals to identify novel biomarkers and deepen their comprehension of complex diseases and potential therapeutic strategies. The company is also working on a streamlined version of its analytical platform to further improve its capabilities in generating insights.

Tagomics is a company focused on enhancing disease diagnosis through advanced multitopic profiling and epigenetic-based technologies. It specializes in the development of chemicals that facilitate the discovery of epigenetic biomarkers, providing a second layer of information to DNA beyond the traditional genetic code. This innovative approach enables the identification of biological markers that are sensitive to lifestyle, environmental factors, and disease states. By concentrating on early detection, particularly for colorectal and other common cancers, Tagomics aims to improve patient outcomes through more effective and cost-efficient diagnostic methods.

ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

Kuano Ltd specializes in developing quantum and AI solutions aimed at molecular design, particularly in the fields of drug discovery and development. Founded in 2020 and based in London, the company integrates quantum simulation with machine learning to create effective enzyme inhibitors. Its innovative discovery platform employs target quantum mapping alongside AI-driven chemistry, facilitating the faster and more efficient development of superior drug candidates. Kuano's technology is applicable across several sectors, including pharmaceuticals, crop protection, and industrial chemistry, ultimately enhancing the quality of new therapeutics while reducing the time required for their discovery.

NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.

Scarlet Therapeutics is focused on developing a novel platform for generating therapeutic red blood cells (tRBCs) aimed at treating various diseases. These engineered red blood cells are designed to carry additional proteins, enhancing their therapeutic potential and allowing them to effectively target a wide array of conditions, including hyperammonemia, hyperoxaluria, metabolic disorders, cancer, and autoimmune diseases. By utilizing cell lines for the production of these therapeutics rather than relying on donated stem cells, Scarlet Therapeutics aims to provide more effective treatments within the healthcare industry, ultimately improving patient outcomes through innovative biotherapeutics.

Five Alarm Bio Ltd. is a drug discovery company founded in 2016 and based in Cambridge, United Kingdom. The company focuses on researching and developing anti-aging therapies aimed at addressing various age-related diseases and limitations. By employing a small molecule strategy, Five Alarm Bio seeks to enhance the body's natural defenses against aging-related damage. Its goal is to create innovative therapeutics that can extend the lifespan of healthy cells and mitigate the onset and progression of aging-related conditions.

Oxford Drug Design focuses on developing innovative therapies to combat drug-resistant infections through advanced drug discovery techniques. The company employs a multidisciplinary research approach that integrates computational chemistry, cheminformatics, mathematics, and cloud computing to enhance the drug discovery process. Its flagship platform, DrugFinder, utilizes cutting-edge technologies to facilitate computer-aided drug discovery, covering all stages from target identification to preclinical studies. By addressing high unmet medical needs, Oxford Drug Design aims to provide healthcare professionals with effective new antibiotics for treating challenging diseases, including cancer and other conditions associated with drug resistance.

52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

Axol Bioscience Ltd., established in 2012 and based in Little Chesterford, United Kingdom, specializes in human cell culture systems for research purposes. The company produces and supplies various types of human cells derived from induced pluripotent stem cells (iPSCs), such as cardiomyocytes, neural stem cells, and astrocytes, along with primary cells like endothelial cells and fibroblasts. Axol also provides essential media, reagents, and growth factors to maintain these cell cultures. Additionally, they offer custom services including iPSC reprogramming, differentiation, genome editing, and cell sourcing tailored to clients' needs. Their products are distributed globally through strategic partners in various countries across Asia, North America, Europe, and internationally.

Qureight is an imaging analytics company focused on enhancing the understanding of respiratory diseases, including Idiopathic Pulmonary Fibrosis and lung cancer. It develops a clinical data curation and analytics platform that integrates technology and life sciences to expedite drug development. By leveraging artificial intelligence, Qureight collaborates with hospitals, pharmaceutical companies, and software developers to analyze extensive clinical datasets. This approach aids in structuring medical images alongside clinical metadata, allowing healthcare professionals to identify novel biomarkers and deepen their comprehension of complex diseases and potential therapeutic strategies. The company is also working on a streamlined version of its analytical platform to further improve its capabilities in generating insights.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on developing innovative solutions that combine prescription drugs with digital therapies. Founded by a team of experienced healthcare professionals and life scientists, the company aims to optimize medication dosing through real-time feedback and linked behavioral therapy to enhance patient outcomes. Currently, Closed Loop Medicine is developing products targeting hypertension and insomnia, alongside a diverse pipeline addressing various chronic diseases. The company prioritizes the needs of both patients and clinicians in the design and development of its offerings, striving to integrate technology effectively within the healthcare system.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

Sanome is focused on addressing the growing demand for healthcare services by enhancing early detection and prevention strategies. The company has developed a predictive analytics tool that aids clinicians in identifying patient health changes earlier, thereby improving decision-making in clinical settings. By integrating healthcare data with advanced artificial intelligence and biophysical biomarkers, including at-home composite tests, Sanome's platform provides actionable clinical insights. This approach enables healthcare providers to detect potential health issues before they escalate, ultimately leading to better patient outcomes and increased operational efficiency. The company's long-term vision includes creating a human digital twin that continuously monitors individual health, informing clinicians about significant changes through its Clinical Co-pilot.

ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

Cytoseek Limited, a spinout from the University of Bristol, develops innovative cell therapies aimed at treating cancer, heart disease, osteoarthritis, and diabetic wound healing. Established in 2017 and based in Bristol, the company utilizes a novel cell membrane augmentation technology that enhances the functionality of cell therapies. This technology enables targeted tissue delivery and improves cell survivability, potentially increasing the efficacy of treatments. Cytoseek is currently conducting proof of principle studies to validate its approach and is actively seeking partnerships with other cell therapy companies to advance these therapies into clinical applications, ultimately striving to improve human health.

Tay Therapeutics is a biotechnology company focused on drug discovery, specifically developing innovative topical and oral therapies for inflammatory skin conditions. The company aims to create alternatives to commonly prescribed steroid creams used for treating diseases like psoriasis and eczema. These steroid treatments can often be ineffective and may lead to significant side effects. By prioritizing the safety and efficacy of their medications, Tay Therapeutics seeks to provide patients with better treatment options for managing their skin diseases.

GeoSpock Limited, established in 2013 and headquartered in Cambridge, UK, with offices in Tokyo and Singapore, specializes in developing a unique, cloud-native database platform, GeoSpock DB. This platform is optimized for querying and analyzing large-scale, location-tagged data, enabling efficient data fusion and rapid, complex queries using SQL. It integrates seamlessly with popular business intelligence tools like Tableau and Power BI, as well as data science environments such as Python Notebooks and Apache Spark. GeoSpock DB caters to a wide range of industries, from real-time logistics tracking to local service applications, unlocking valuable insights from diverse IoT data sources.

Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.

Kalium Health Ltd is a company focused on improving kidney care through innovative medical technology. Based in Cambridge, United Kingdom, it designs and manufactures a finger-prick blood test specifically for measuring blood potassium concentration. This test aims to facilitate early treatment for patients, reducing the complications and costs associated with traditional testing methods. By leveraging advanced electrolyte sensing technology, Kalium Health provides patients with accurate, real-time data essential for managing cardiorenal diseases. The company’s first product addresses a significant risk in kidney disease, a condition that imposes substantial financial burdens on healthcare systems. With a clear regulatory pathway and a targeted market strategy, Kalium Health is poised to transform patient care and enhance outcomes for millions affected by kidney disease.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.